Company intelligence / Profile preview
Zhejiang Kanglaite Pharmaceutical Co., Ltd.
Hangzhou, Zhejiang, Chinapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Employees
- ~550
- Development stage
- Commercial
01
Overview
Kanglaite (KLT) is an approved anticancer drug in China since 1997. It has shown effectiveness in treating various cancers and cancer cachexia. The drug has been used by over 700,000 patients in 3,000 hospitals in China. Clinical trials are ongoing for cancer cachexia treatment.
- Therapeutic areas
- Oncology
- Modalities
- Traditional Chinese MedicineHerbal medicines
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Zhejiang Kanglaite Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Kanglaite Pharmaceutical Co., Ltd..